| Literature DB >> 34805352 |
Sishi Cai1, Ye Yang2, Jue Pan1, Qing Miao1, Wenting Jin1, Yuyan Ma1, Chunmei Zhou3, Xiaodong Gao4, Chunsheng Wang2, Bijie Hu1,4.
Abstract
BACKGROUND: Metagenomic next-generation sequencing (mNGS) is widely applied in the etiological diagnosis of infectious diseases. However, the clinical practice of mNGS in infective endocarditis (IE) is relatively less studied. This research aimed to assess the etiological diagnostic value of valve mNGS in IE.Entities:
Keywords: Metagenomic next-generation sequencing (mNGS); culture negative infective endocarditis; etiological diagnosis; infective endocarditis (IE)
Year: 2021 PMID: 34805352 PMCID: PMC8573444 DOI: 10.21037/atm-21-2488
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Flowchart of participant recruitment and collection of samples. From a total of 63 patients, 57 were finally included in the analysis. Among them, 8 participants were admitted with non-infective valvular diseases and 49 were definite IE according to the modified Duke criteria. A total of 28 IE patients were blood culture or valve culture positive. Both blood culture and valve culture were negative in the remaining 21 IE participants. mNGS, metagenomic next-generation sequencing; IE, infective endocarditis.
Characteristics of the 57 participants
| Characteristics | IE patients (n=49) | Patients with non-infective valvular heart diseasesa (n=8) |
|---|---|---|
| Age, year | 50 (35, 59) | 47 (36, 63) |
| Gender, male, No. (%) | 35 (71.4) | 5 (62.5) |
| NVE, No. (%) | 43 (87.8) | None |
| PVE, No. (%) | 6 (12.2) | None |
| Basic diseases, No. (%) | ||
| Valvular diseasesb | 27 (55.1) | 8 (100.0) |
| Other basic diseasesc | 12 (24.5) | 1 (12.5) |
| Culture positive, No. (%) | 28 (57.1) | None |
| Duration of diseased, day | 60 (30, 90) | 180 (90, 225) |
| Laboratory data | ||
| WBC, ×109/L (reference range, 3.5–9.5) | 8.9 (5.9, 10) | 6.5 (5.8, 7.5) |
| Percentage of neutrophils, % (reference range, 40–75) | 70.5 (63.4, 75.7) | 62.5 (55.3, 70.5) |
| ESR, mm/H (reference range, 0–20) | 21 (13, 33) | 11 (8, 15) |
| CRP, mg/L (reference range, 0–3.0) | 12.7 (4.9, 40.1) | 1.1 (0.3, 1.9) |
| PCT, ng/mL (reference range, 0–0.5) | 0.1 (0.05, 0.4) | Not available |
| Echocardiogram manifestation, No. (%) | ||
| Vegetation | 42 (85.7) | None |
| Abscess | 3 (6.1) | None |
| Perforation | 18 (36.7) | None |
| Antibiotics used before admission, No. (%) | 46 (93.9) | None |
a, including rheumatic valvular disease (n=5) and congenital valvular disease (n=3); b, including rheumatic valvular disease, congenital valvular disease, and degenerative valvular disease; c, including diabetes mellitus, chronic renal failure, liver cirrhosis, malignant tumor, long term administration of glucocorticoid, or other kinds of immunocompromised conditions; d, from onset of fever, chest tightness, shortness of breath, or other symptoms to admission. NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PCT, procalcitonin.
Figure 2Pathogens of IE detected by valve mNGS and number of cases. mNGS, metagenomic next-generation sequencing; IE, infective endocarditis.
The main types of microbes in culture-positive IE
| Microbes in culture-positive IE | Number of cases (n=28) | Constituent ratios (%) |
|---|---|---|
| Gram-positive bacteria | 25 | 89.3 |
| | 13 | 46.4 |
| | 4 | 14.3 |
| Other Gram-positive bacteria | 8 | 28.6 |
| Gram-negative bacteria | 2 | 7.1 |
| Fungi | 1 | 3.6 |
IE, infective endocarditis.
Figure 3Representative result images of MALDI-TOF mass spectrometry of culture isolates. (A) MALDI-TOF mass spectrometry identified blood culture isolate of P19 as Granulicatella adiacens; (B) MALDI-TOF mass spectrometry identified blood culture isolate of P22 as Candida parapsilosis; (C) MALDI-TOF mass spectrometry identified blood culture isolate of P23 as Erysipelothrix rhusiopathiae; (D) MALDI-TOF mass spectrometry identified blood culture isolate of P24 as Abiotrophia defective. MALDI-TOF mass spectrometry, Matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
The differences of valve mNGS results between culture-positive IE and culture-negative IE patients
| Parameters of mNGS results | Culture-positive IE | Culture-negative IE | P value |
|---|---|---|---|
| SMRNG | 32,209 (9,518, 179,897) | 7,032 (1,278, 24,719) | 0.0199 |
| Relative abundance of genera | 97.4% (94.1%, 98.2%) | 84.8% (68.7%, 96.8%) | 0.0063 |
| SMRN | 28,596 (5,250, 157,095) | 3,480 (815, 15,005) | 0.024 |
| Relative abundance of species | 75.4% (66.0%, 95.7%) | 63.9% (52.2%, 76.1%) | 0.0161 |
| Coverage rate | 41.5% (16.7%, 75.6%) | 14.2% (3.4%, 47.8%) | 0.043 |
mNGS, metagenomic next-generation sequencing; IE, infective endocarditis; SMRNG, stringent mapped reads number of genera; SMRN, stringent mapped reads number.
Valve mNGS optimizing antibiotic treatment in culture-negative IE patients
| Patient ID | Type of IE | Pathogens identified by valve mNGS | Initial antibiotic regimen before mNGS | Adjusted antibiotic regimen after mNGS |
|---|---|---|---|---|
| 30 | NVE |
| Daptomycin | Ceftriaxone |
| 34 | NVE |
| Vancomycin + meropenem | Ceftriaxone + Amikacin |
| 35 | NVE |
| Vancomycin + meropenem | Cefuroxime |
| 38 | NVE |
| Daptomycin | Ceftriaxone |
| 40 | NVE |
| Vancomycin + imipenem cilastatin | Ceftriaxone + Amikacin |
| 42 | PVE |
| Vancomycin + meropenem | Ceftriaxone + Amikacin |
mNGS, metagenomic next-generation sequencing; IE, infective endocarditis; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis.